Background stories of how others approached and experienced their European Horizon funding trajectory.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
Read the full article for detailsProfessor Inez Germeys leads the Center for Contextual Psychiatry at KU Leuven, which is a large multi-disciplinary research group focusing on the interaction between the person and the environment in the development of psychopathology. She has received a European Research Council (ERC) Consolidator grant (INTERACT) and Proof of Concept grant (IMPACT). With these grants professor Germeys and her team researched a new mobile self-management therapy for patients with a psychotic disorder. The Acceptance and Commitment Therapy in Daily Life (ACT-DL) was further developed for the clinical environment. In line with that the Horizon 2020 IMMERSE project aims to thoroughly evaluate strategies, processes, and outcomes of implementing a digital mobile mental health solution.